A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia
NCT06709131 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2025-11-24
Summary
A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Conditions
- Relapsed/Refractory Acute Myeloid Leukemia(AML)
Interventions
- DRUG
-
CAR-T cells（ chimeric antigen receptor T cells）
CAR-T cells（ chimeric antigen receptor T cells）
Sponsors & Collaborators
-
He Huang
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-08
- Primary Completion
- 2025-08-17
- Completion
- 2026-08-17
Countries
- China
Study Locations
More Related Trials
-
Donor-derived CAR-T Cells in the Treatment of AML Patients
NCT04766840 ·Status: UNKNOWN ·Phase: PHASE1
-
Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT04835519 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
NCT06499025 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1
-
A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
NCT07043218 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
NCT06756321 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
NCT05309213 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia
NCT04923919 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
NCT04271800 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
NCT04272125 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma
NCT05745181 ·Status: RECRUITING ·Phase: PHASE2
-
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
NCT04271410 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
NCT06718270 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML
NCT05473221 ·Status: UNKNOWN ·Phase: PHASE1
-
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
NCT04265963 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
NCT05672147 ·Status: RECRUITING ·Phase: PHASE1
-
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
NCT05909527 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）
NCT03544021 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
NCT05488132 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
NCT05618041 ·Status: RECRUITING ·Phase: NA
-
Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.
NCT06786299 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients
NCT03902197 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)
NCT04803929 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies
NCT04007978 ·Status: UNKNOWN ·Phase: PHASE1
-
CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia
NCT04154709 ·Status: UNKNOWN ·Phase: PHASE1
-
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
NCT06209671 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1